Puma Biotechnology Aims to Revolutionize Cancer Care with Innovative Drug Candidates Los Angeles-based Puma Biotechnology, Inc., a biopharmaceutical company, is dedicated to developing and commercializing next-generation therapies to transform cancer care, both in the US and abroad. Puma Biotechnology focuses on bringing novel products to market that harness cutting-edge technology to tackle a range of cancers. Among Puma Biotechnology's standout drug candidates is PB272 (neratinib, oral), which targets early-stage HER2-overexpressed/amplified breast cancer. The company is also exploring the use of neratinib in combination with capecitabine to treat advanced or metastatic HER2-positive breast cancer and HER2 mutation-positive solid tumors. Other pipeline products include PB272 (neratinib, intravenous) and PB357. Puma Biotechnology has secured a number of key partnerships to support its mission, including a license agreement with Pfizer and sub-license agreements with CANbridge BIOMED Limited, Bixink Therapeutics Co., Ltd., Knight Therapeutics, Inc., Pint Pharma International SA, Pierre Fabre Medicament SAS, and Specialised Therapeutics Asia Pte Ltd. Founded in 2010, Puma Biotechnology is making impressive strides in its efforts to combat cancer and is poised to play a pivotal role in driving forward the next wave of cancer therapies.
Puma Biotechnology's ticker is PBYI
The company's shares trade on the NYSE stock exchange
They are based in Los Angeles, California
There are 51-200 employees working at Puma Biotechnology
It is pumabiotechnology.com
Puma Biotechnology is in the Healthcare sector
Puma Biotechnology is in the Biotechnology industry
The following five companies are Puma Biotechnology's industry peers: